Tags : Vilobelimab

InflaRx Reports Results of Vilobelimab in P- II IXPLORE Study

Tuba Khan May 12, 2021

Shots: The P-II IXPLORE study involves assessing vilobelimab (400/800mg, q2w) + SOC vs PBO + SOC in 19 patients with ANCA associated vasculitis or AAV in the US The therapy […]readmore

Tags : Vilobelimab

InflaRx Reports Results of Vilobelimab in P- II IXPLORE Study

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Vilobelimab

InflaRx Reports Results of Vilobelimab in P- II IXPLORE Study

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company